Evidence map›Paper›PMID 41858572›Full record

ReviewInternational journal of nanomedicine2026

Nano-Enabled Therapeutics: Novel Strategies for Preeclampsia Treatment.

Yimin Huang, Xiaojuan Zhang, Lili Xue, Chuanchuan He

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yimin HuangDepartment of Central Laboratory, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People's Republic of China.
Xiaojuan ZhangDepartment of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing, People's Republic of China.
Lili XueDepartment of Obstetrics, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People's Republic of China.
Chuanchuan HeDepartment of Central Laboratory, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preeclampsia (PE), a pregnancy-specific disorder characterized by hypertension and placental dysfunction, remains a leading cause of maternal and fetal morbidities worldwide. Recent advances in nanomedicine offer promising therapeutic strategies by targeting placental pathologies. Studies have demonstrated that in PE mouse models, the regulation of key disease-related genes (such as sFlt1 and VEGF) using siRNA- or mRNA-loaded carriers (eg, lipid nanoparticles, exosomes, or elastin-like polypeptides) can effectively alleviate PE symptoms. This review summarizes the progress in nanoparticle-based therapies for PE, discusses challenges such as scalability and clinical translation, and highlights the potential of nanomedicine to revolutionize PE management.

Indexed as

NanomedicineNanoparticle Drug Delivery SystemNanoparticlesPre-EclampsiaAnimalsFemaleHumansMicePregnancyRNA, Small InterferingVascular Endothelial Growth Factor Receptor-1Nanoparticle Drug Delivery SystemRNA, Small InterferingVascular Endothelial Growth Factor Receptor-1nanocarrierplacentapreeclampsiasFlt1

Identifiers

PMID41858572
PMCPMC12998963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.